Call us directly: NY: 1-631-893-3903 or NJ: 1-201-342-7662

Or visit one of our three locations: View Locations

Click here to see our five-star patient satisfaction reviews on Healthgrades

Jun 5

Stem Cells: The Next Frontier documentary screening for investors in NYC.

BHI Therapeutic Sciences (BHITS) and Brian Mehling, M.D. hosted a private screening of Stem Cells: The Next Frontier on Tuesday, February 13 in New York. The evening included a Q & A session and information on how to participate by becoming an investor to make these life-saving stem cells therapies more accessible to patients across the globe.
“At BHITS, our philosophy is that stem cells are the future of medicine and we are excited to share our ideas with the general public and investors. BHITS is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvested from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby),” said Dr. Mehling. “Stem cells are a unique kind of cell that can be used to regenerate the human body without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain,” he added.
“BHITS has a treatment and research facility in Slovakia, as well as clinic facilities in China and Jamaica. Our medical and scientific teams have published research on the more than 3,000 stem cell treatments have been successfully performed in our clinics,” said Doreen Santora, chief executive officer of BHITS.

Kirk Barton, a retired NFL player, attended the screening. Mr. Barton was a member of the Miami Dolphins, San Francisco 49ers, Cincinnati Bengals, Denver Broncos and a college standout at Ohio State University, sustaining many injuries during his football career.

“It’s a demanding sport. I’ve torn my PCL, MCL, meniscus, shoulder etc. multiple times. I’ve done some research and I decided to try the stem cell therapy offered to me by Dr.Mehling at BHITS in Jamaica. It was like getting a new knee. I never felt better. I recommend it to ton of people because I believe in it,” he said.

His Excellencey Peter Kmec, Ambassador Extraordinary and Plenipotentiary, who served as the Ambassador of Slovakia to the U.S. since September 2012 attended the documentary screening and shared his insight afterwards.

“I was pleased to learn from Katarina Novakova, who spearheaded the BHITS activities in Slovakia, they’ve had more than 250 patients treated in their facility. I am proud of the company’s innovative approach and wish them success with their future endeavors in Slovakia,” said H.E. Ambassador Kmec.

“Innovation is on the top of our current agenda as well. We created a Slovak-American Business and Innovation Council (SABIC) in 2016, through which we would like to channel projects linked to startups, innovation, research, and development and to deepen trade and investment between Slovakia and US. Our goal is to help improve the Slovak innovation ecosystem through bilateral cooperation and to bring Slovakia into the family of the most competitive economies,” he added.

BHITS has conducted several clinical studies testing the safety and efficacy of human umbilical cord blood (hUCB) stem cells. Its clinical studies have provide support for the short and long-term safety of hUCB stem cells for therapy of different medical conditions, including chronic inflammation, musculoskeletal conditions, stroke and spinal cord injury. Its intent is to develop hUCB product-based therapies in Investigational New Drug Phase 1 clinical trials in order to extend lifespans and improve the quality of life for patients.

BHITS is for looking for accredited investors. The offering can be requested by emailing [email protected]